

OPTUMRx ORPHAN DRUG PROGRAM

Targeted strategy to help control growing costs

-  Up to **30 million** Americans affected by one of 7,000 rare diseases.¹
-  Orphan drugs **cost up to \$750,000/year**.²
-  Orphan drugs are **17%** of worldwide drug sales.³

BRINGING SAVINGS TO LIFE

Trained pharmacists can help optimize care.

Industry benchmarks and OptumRx data show the impact of advanced clinical counseling to achieve optimal value for orphan drug therapies.

-  Optimal dosing
-  Confirmed drug safety, effectiveness
-  Flag discontinuation and/or alternative drug options

BASELINE ASSUMPTIONS

-  50,000 average members
 -  Average orphan drug cost: \$147,000 per user/per year⁴
 -  On average **15 members** (~0.03%) use one of 19 targeted orphan drugs
- **\$2,205,000/year total** targeted orphan drug spend (15 x \$123,000)

BIG SAVINGS ARE POSSIBLE

-20%
Total targeted orphan drug spend


Of 15 members who use a targeted orphan drug we assume 6-10 will enroll in the program
Of these, we assume 1-3 members will modify therapy

Potential savings: \$369,000/year
(3 members who modify their therapy @ \$123,000)

Cost of OptumRx Orphan Drug Management Program = \$300 per engaged member per year

PROGRAM DESIGN

WE EVALUATED OVER 2,000 ORPHAN DRUGS:



These targeted drugs present multiple opportunities for pharmacists to optimize care.

Clinical evidence demonstrates high risk for:

- Complicated dosing
- Significant adverse events
- Elevated potential for ineffective therapy

We engage the prescribing physicians to advise when clinically appropriate therapy changes are needed.

See how we can help. Visit our [resource library](#).

About OptumRx

OptumRx is a pharmacy care services company helping clients and more than 65 million members achieve better health outcomes and lower overall costs through innovative prescription drug benefit services, including network claims processing, clinical programs, formulary management and specialty pharmacy care. OptumRx is part of Optum®, a leading information and technology-enabled health services business dedicated to making the health system work better for everyone. For more information, visit optum.com/optumrx.

1. IQVIA Institute. [Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments](#). Published October, 2018.
2. Managed Care. Orphan drugs: Way too many, way too expensive. June 4, 2017.
3. EvaluatePharma® Orphan Drug Report May, 2018.
4. Managed Care. Orphan drugs: Way too many, way too expensive. Published June 4, 2017.